Table 3– Resistance to second-line drugs among new, previously treated and all multidrug-resistant (MDR)-tuberculosis (TB) cases, and among new, previously treated and all TB cases
ResistanceCases with MDR-TBAll cases with TB§
New#Previously treatedAll+NewPreviously treatedAll
Ofx14.5 (4.9–24.2)46.2 (32.1–60.2)29.9 (21.1–38.7)6.1 (2.2–10.0)38.7 (26.2–51.2)15.8 (10.8–20.8)
Km18.2 (7.7–28.7)36.5 (23.0–50.1)27.1 (18.5–35.7)7.5 (3.2–11.8)32.3 (20.3–44.2)14.8 (10.0–19.7)
Amk16.4 (6.3–26.5)26.9 (14.5–39.4)21.5 (13.6–29.4)6.8 (2.7–10.9)24.2 (13.2–35.2)12.0 (7.5–16.4)
Cm16.4 (6.3–26.5)25.0 (12.8–37.2)20.6 (12.8–28.3)6.9 (2.7–11.1)21.3 (10.7–31.9)11.2 (6.9–15.6)
Injectable agentsƒ18.2 (7.7–28.7)36.5 (23.0–50.1)27.1 (18.5–35.7)7.5 (3.2–11.8)32.3 (20.3–44.2)14.8 (10.0–19.7)
XDR5.5 (0.0–11.7)23.1 (11.2–34.9)14.0 (7.3–20.7)2.0 (0.0–4.4)19.4 (9.2–29.5)7.2 (3.6–10.7)
  • Data are presented as percentage of proportion (95% CI). Ofl: ofloxacin; Km: kanamycin; Amk: amikacin; Cm: capreomycin; XDR: extensively drug resistant (resistance to Ofx plus resistance to Km and/or Amk and/or Cm). #: n=55; : n=52; +: n=107; §: number of patients tested for new, previously treated and all cases were 147, 62 and 209, respectively, expect for Cm which were 144, 61 and 205, respectively; ƒ: Km and Amk.